Published online before print November 25, 2002, doi: 10.1161/01.HYP.0000050101.90932.14
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;41:99.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
Cardiac Angiotensin II Type 2 Receptor Activates the Kinin/NO System and Inhibits Fibrosis
From the First Department of Internal Medicine (S.K., T.I., H.S., H. Matsuura, K.C.) and Clinical Laboratory Medicine (R.O., T.O., M.K.), Second Department of Physiology (Y.T.), Hiroshima University School of Medicine, Hiroshima, Japan; and Internal Medicine II, Kansai Medical University (O.I., K.A., H. Matsubara), Osaka, Japan.
Correspondence to Ryoji Ozono, MD, Department of Clinical Laboratory Medicine, Hiroshima University Faculty of Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima, Japan 734-8551. E-mail ozono{at}hiroshima-u.ac.jp
We have previously demonstrated that stimulation of the angiotensin (Ang) II type 2 receptor in vascular smooth muscle cells caused bradykinin production by activating kininogenase in transgenic mice. The aim of this study was to determine whether overexpression of AT2 receptors in cardiomyocytes attenuates Ang II–induced cardiomyocyte hypertrophy or interstitial fibrosis through a kinin/nitric oxide (NO)-dependent mechanism in mice. Ang II (1.4 mg/kg per day) or vehicle was subcutaneously infused into transgenic mice and wild-type mice for 14 days. The amount of cardiac AT2 receptor relative to AT1 receptor in transgenic mice was 22% to 37%. Ang II caused similar elevations in systolic blood pressure (by 
45 mm Hg) in transgenic mice and wild-type mice. Myocyte hypertrophy assessed by an increase in myocyte cross-sectional area, left ventricular mass, and atrial natriuretic peptide mRNA levels were similar in transgenic and wild-type mice. Ang II induced prominent perivascular fibrosis of the intramuscular coronary arteries, the extent of which was significantly less in transgenic mice than in wild-type mice. Inhibition of perivascular fibrosis in transgenic mice was abolished by cotreatment with HOE140, a bradykinin B2 receptor antagonist, or L-NAME, an inhibitor of NO synthase. Cardiac kininogenase activity was markedly increased (2.6-fold, P<0.001) after Ang II infusion in transgenic mice but not in wild-type mice. Immunohistochemistry indicated that both bradykinin B2 receptors and endothelial NO synthase were expressed in the vascular endothelium, whereas only B2 receptors were present in fibroblasts. These results suggest that stimulation of AT2 receptors present in cardiomyocytes attenuates perivascular fibrosis by a kinin/NO-dependent mechanism. However, the effect on the development of cardiomyocyte hypertrophy was not detected in this experimental setting.
Key Words: receptors, angiotensin II • kinins • mice • fibrosis • hypertrophy
This article has been cited by other articles:
 |
|
 |
|
  P. Castro-Chaves, R. Fontes-Carvalho, M. Pintalhao, P. Pimentel-Nunes, and A. F. Leite-Moreira Angiotensin II-induced increase in myocardial distensibility and its modulation by the endocardial endothelium in the rabbit heart Exp Physiol, June 1, 2009; 94(6): 665 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Calo, M. Puato, S. Schiavo, M. Zanardo, C. Tirrito, E. Pagnin, G. Balbi, P. A. Davis, P. Palatini, and P. Pauletto Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2804 - 2809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mito, R. Ozono, T. Oshima, Y. Yano, Y. Watari, Y. Yamamoto, A. Brydun, K. Igarashi, and M. Yoshizumi Myocardial Protection Against Pressure Overload in Mice Lacking Bach1, a Transcriptional Repressor of Heme Oxygenase-1 Hypertension, June 1, 2008; 51(6): 1570 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yan, A. J. T. Schuldt, R. L. Price, I. Amende, F.-F. Liu, K. Okoshi, K. K. L. Ho, A. J. Pope, T. K. Borg, B. H. Lorell, et al. Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing AT2 receptors in ventricular myocytes Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1274 - H1281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Li, T. Kondo, Y. Numaguchi, K. Kobayashi, M. Aoki, N. Inoue, K. Okumura, and T. Murohara Role of Bradykinin, Nitric Oxide, and Angiotensin II Type 2 Receptor in Imidapril-Induced Angiogenesis Hypertension, February 1, 2008; 51(2): 252 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Toda, K. Ayajiki, and T. Okamura Interaction of Endothelial Nitric Oxide and Angiotensin in the Circulation Pharmacol. Rev., March 1, 2007; 59(1): 54 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chandrashekhar Embracing Diversity in Remodeling: A Step in Therapeutic Decision Making in Heart Failure? J. Am. Coll. Cardiol., February 20, 2007; 49(7): 822 - 825. [Full Text] [PDF]
|
|
|
|
|
|
C. Savoia, R. M. Touyz, M. Volpe, and E. L. Schiffrin Angiotensin Type 2 Receptor in Resistance Arteries of Type 2 Diabetic Hypertensive Patients Hypertension, February 1, 2007; 49(2): 341 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Barker, M. P. Massett, V. A. Korshunov, A. M. Mohan, A. J. Kennedy, and B. C. Berk Angiotensin II Type 2 Receptor Expression After Vascular Injury: Differing Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade Hypertension, November 1, 2006; 48(5): 942 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Shariat-Madar, F. Mahdi, M. Warnock, J. W. Homeister, S. Srikanth, Y. Krijanovski, L. J. Murphey, A. A. Jaffa, and A. H. Schmaier Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin Blood, July 1, 2006; 108(1): 192 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liao, S. Takashima, H. Zhao, Y. Asano, Y. Shintani, T. Minamino, J. Kim, M. Fujita, M. Hori, and M. Kitakaze Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice Cardiovasc Res, April 1, 2006; 70(1): 107 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Warnecke, P. Mugrauer, D. Surder, J. Erdmann, C. Schubert, and V. Regitz-Zagrosek Intronic ANG II type 2 receptor gene polymorphism 1675 G/A modulates receptor protein expression but not mRNA splicing Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2005; 289(6): R1729 - R1735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D'Amore, M. J. Black, and W. G. Thomas The Angiotensin II Type 2 Receptor Causes Constitutive Growth of Cardiomyocytes and Does Not Antagonize Angiotensin II Type 1 Receptor-Mediated Hypertrophy Hypertension, December 1, 2005; 46(6): 1347 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pedram, M. Razandi, M. Aitkenhead, and E. R. Levin Estrogen Inhibits Cardiomyocyte Hypertrophy in Vitro: ANTAGONISM OF CALCINEURIN-RELATED HYPERTROPHY THROUGH INDUCTION OF MCIP1 J. Biol. Chem., July 15, 2005; 280(28): 26339 - 26348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Carey Cardiovascular and Renal Regulation by the Angiotensin Type 2 Receptor: The AT2 Receptor Comes of Age Hypertension, May 1, 2005; 45(5): 840 - 844. [Full Text] [PDF]
|
|
|
|
|
|
B. L. Falcon, S. J. Veerasingham, C. Sumners, and M. K. Raizada Angiotensin II Type 2 Receptor-Mediated Gene Expression Profiling in Human Coronary Artery Endothelial Cells Hypertension, April 1, 2005; 45(4): 692 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liao, M. Asakura, S. Takashima, A. Ogai, Y. Asano, H. Asanuma, T. Minamino, H. Tomoike, M. Hori, and M. Kitakaze Benidipine, a long-acting calcium channel blocker, inhibits cardiac remodeling in pressure-overloaded mice Cardiovasc Res, March 1, 2005; 65(4): 879 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Booz Putting the Brakes on Cardiac Hypertrophy: Exploiting the NO-cGMP Counter-Regulatory System Hypertension, March 1, 2005; 45(3): 341 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. Falcon, J. M. Stewart, E. Bourassa, M. J. Katovich, G. Walter, R. C. Speth, C. Sumners, and M. K. Raizada Angiotensin II type 2 receptor gene transfer elicits cardioprotective effects in an angiotensin II infusion rat model of hypertension Physiol Genomics, November 17, 2004; 19(3): 255 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liao, M. Asakura, S. Takashima, A. Ogai, Y. Asano, Y. Shintani, T. Minamino, H. Asanuma, S. Sanada, J. Kim, et al. Celiprolol, A Vasodilatory {beta}-Blocker, Inhibits Pressure Overload-Induced Cardiac Hypertrophy and Prevents the Transition to Heart Failure via Nitric Oxide-Dependent Mechanisms in Mice Circulation, August 10, 2004; 110(6): 692 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Metcalfe, M. J. Huentelman, L. D. Parilak, D. G. Taylor, M. J. Katovich, H. J. Knot, C. Sumners, and M. K. Raizada Prevention of Cardiac Hypertrophy by Angiotensin II Type-2 Receptor Gene Transfer Hypertension, June 1, 2004; 43(6): 1233 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Johren, A. Dendorfer, and P. Dominiak Cardiovascular and renal function of angiotensin II type-2 receptors Cardiovasc Res, June 1, 2004; 62(3): 460 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Collins, J. Schnee, W. Wang, S. Kim, M. C. Fishbein, D. Bruemmer, R. E. Law, S. Nicholas, R. S. Ross, and W. A. Hsueh Osteopontin modulates angiotensin II- induced fibrosis in the intact murine heart J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1698 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Bove, Z. Yang, W. D. Gilson, F. H. Epstein, B. A. French, S. S. Berr, S. P. Bishop, H. Matsubara, R. M. Carey, and C. M. Kramer Nitric Oxide Mediates Benefits of Angiotensin II Type 2 Receptor Overexpression During Post-Infarct Remodeling Hypertension, March 1, 2004; 43(3): 680 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Carey and H. M. Siragy Newly Recognized Components of the Renin-Angiotensin System: Potential Roles in Cardiovascular and Renal Regulation Endocr. Rev., June 1, 2003; 24(3): 261 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Oishi, R. Ozono, Y. Yano, Y. Teranishi, M. Akishita, M. Horiuchi, T. Oshima, and M. Kambe Cardioprotective Role of AT2 Receptor in Postinfarction Left Ventricular Remodeling Hypertension, March 1, 2003; 41(3): 814 - 818. [Abstract] [Full Text] [PDF]
|
|